On May 22, 2025, Gyre Therapeutics, Inc. entered into an underwriting agreement to sell 2,222,222 shares of common stock at $9.00 per share, expecting to raise about $18.5 million for clinical trials and general purposes. The offering is expected to close on May 27, 2025.